Loading...
•
Mar 31, 2025
Schrodinger Q1 2025 Earnings Report
Schrodinger reported financial results for the first quarter ended March 31, 2025.
Key Takeaways
Schrödinger reported strong performance in the first quarter of 2025, with total revenue increasing 63% year-over-year to $59.6 million, driven by significant growth in both software and drug discovery segments. The company reported a GAAP net loss of $59.8 million and a non-GAAP net loss of $46.7 million for the quarter.
Total revenue for Q1 2025 was $59.6 million, a 63% increase compared to Q1 2024.
Software revenue grew 46% year-over-year to $48.8 million in Q1 2025.
Drug discovery revenue saw substantial growth, increasing 237% to $10.7 million in Q1 2025.
The company reported a GAAP net loss of $59.8 million and a non-GAAP net loss of $46.7 million for the quarter.
Revenue by Segment
Forward Guidance
Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2025. For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.
Positive Outlook
- Maintained full-year 2025 financial guidance.
- Anticipates continued software revenue in Q2 2025.
- Proprietary pipeline is progressing.
- Initial SGR-1505 Phase 1 clinical data expected in June.
- Fortifying position in computational solutions for R&D.
Challenges Ahead
- Specific full-year revenue or earnings figures were not updated in the report.
- Q2 2025 software revenue guidance range implies potential variability ($38M - $42M).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...